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483 A NOVEL CELLULAR IMPLANTATION SYSTEM USING AN
INJECTABLE ULTRA-PURIFIED ALGINATE GEL FOR
ARTHROSCOPIC REPAIR OF OSTEOCHONDRAL DEFECTS
T. Igarashi, N. Iwasaki, Y. Kasahara, A. Minami. Department of
Orthopaedic Surgery, Hokkaido University School of Medicine, Sapporo,
JAPAN
Purpose: To determine the superiority of chondrogenic potential from
BMSCs using an ultra-puriﬁed alginate gel over a commercial grade one
and to assess the reparative tissues treated with BMSCs and a puriﬁed
alginate in rabbit cartilage defect model.
Methods: Ultra-puriﬁed alginate (Sea Matrix®, Mochida Pharma., Japan,
endotoxin level of 5.76 EU/g) and commercial grade one (Sodium Alginate
500, Wako, Japan, endotoxin level of 75,950 EU/g) were prepared.
Cytotoxicity of CaCl2 : BMSCs in alginate were exposed to 50, 100, 200,
and 400mM CaCl2. The living cells were counted with Cell Counting
Kit-8 (CCK-8). Proliferation assay : BMSCs encapsulated in puriﬁed and
commercial grade alginate beads were cultured in DMEM with 10%
FBS. At 0, 1, 2, 3, and 7 days, the viable cells were counted with
CCK-8. Alginate beads culture: Alginate beads containing BMSCs were
cultured in chondrogenic medium containing TGF-b3. At 7 and 14 days,
relative gene expressions were analyzed by real-time RT-PCR. At 14 and
21 days, each alginate bead was histologically evaluated. Rabbit model:
The defects (Ø5mm) were created in the patella groove and divided
into ﬁve groups: defect (no treatment); CAlg, commercial grade alginate
alone; CAlgC, commercial grade alginate with BMSCs; PAlg, puriﬁed
alginate alone; PAlgC, puriﬁed alginate with BMSCs. To avoid excessive
exposure to a cytotoxic CaCl2, CaCl2 was injected to the surface of
alginate. It needed no any ﬁxation. In-vivo evaluation: At 4 and 12 weeks,
the macroscopic and histological ﬁndings were scored with a grading
scale, and the mechanical properties were measured by indentation test.
Cadaver model: The stained alginate gel was injected into the defect
with our novel technique. After the operation, manual mobilization was
intermittently performed. Statistical Analysis: Comparison was assessed
by an ANOVA followed by multiple-comparison post hoc tests. P< 0.05
was statistically considered signiﬁcant.
Results: Cytotoxicity of CaCl2 : The cell number in the 200 and 400mM
groups signiﬁcantly decreased, compared to the other groups (p< 0.05).
Proliferation assay : From 1 to 7 days, the number of living cells in the
puriﬁed alginate gel was signiﬁcantly higher (p< 0.05). Alginate beads
culture: The levels of aggrecan and sox 9 genes in the puriﬁed alginate
at 14 days were signiﬁcantly higher (p< 0.05). The proliferated BMSCs
and a newly synthesized matrix were observed within pore spaces in the
both alginate. Rabbit model: The surface of the defect group was rough
and depressed. In the PAlg and PAlgC groups, the defects were substi-
tuted with ﬁrm and white cartilage-like tissue. The macroscopic score at
12 weeks in the PAlgC group was signiﬁcantly superior to the CAlg and
CAlgC groups (p< 0.05). Histological ﬁndings: In the CAlg and CAlgC
groups, residual alginate gels were found, and inﬂammatory reactions
were found in subchondral bone lesion. The PAlgC group exhibited the
normal cartilaginous structures. The histological scores at 12 weeks were
signiﬁcantly higher in the PAlg and PAlgC groups than in the defect and
CAlg groups (p< 0.05). Mechanical properties: From 4 to 12 weeks, the
modulus of the CAlgC and PAlgC groups signiﬁcantly improved (p< 0.05)
and approximately reached to 80% of normal. Cadaver model: After
mobilization, the alginate gel was not detached and maintained the initial
shape and hardness.
Conclusions: We conﬁrm that the puriﬁed alginate gel has a great
promise as a cell-carrier material for a clinical immnoisolated implantation
of cells into cartilage defects. This study showed a clinical possibility
of arthroscopic implantation using the current injectable system to the
articular cartilaginous lesions.
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Purpose: Articular cartilage shows poor intrinsic repair, leading to
progressive joint damage. Therapies like marrow stimulation or tissue
engineering of cartilage depend on the chondrogenic differentiation of
progenitor cells. However, this chondrogenic differentiation needs to take
place in a diseased joint with an altered environment. We postulate
that catabolic factors in this environment will inhibit chondrogenesis of
progenitor cells.
Methods: We examined the effect of interleukin-1 (Il-1) and tumour
necrosis factor alpha (TNFalpha) on human mesenchymal stem cells
undergoing chondrogenic differentiation. In addition, osteoarthritis syn-
ovium derived conditioned medium was added to human mesenchymal
stem cells undergoing chondrogenic differentiation. Chondrogenesis was
examined by determining the mRNA levels of the chondrogenic markers
collagen type II and aggrecan. Additionally, the hypertrophy marker col-
lagen type X was examined. Proteoglycan deposition was analyzed by
safranin O staining of histological sections.
Results: Chondrogenesis of human mesenchymal stem cells, as deter-
mined by safranin O proteoglycan staining, was completely abolished
at day 14 by adding Il-1 (10 ng/mL) from day 0, 3, 7 and 10 onwards.
Under these conditions the expression of type II collagen and aggrecan
mRNA as well as the hypertrophy marker collagen type X were also
blocked completely, except by late addition of Il-1 (day 10), resulting in
only a partial inhibition of these mRNA markers. Il-1 appears to be a very
potent inhibitor of chondrogenesis, not only at the onset, but throughout
the process of chondrogenesis
Il-1 as well as TNF-alpha inhibited chondrogenesis in a dose-dependent
manner. Even at the lowest dose tested (0.1 ng/mL) Il-1 and TNFalpha
downregulated the mRNA levels of collagen II, aggrecan and collagen
type X. However, TNFalpha showed less potent effects on this downreg-
ulation than Il-1. Moreover, TNFalpha did not inhibit safranin O staining
completely even at the highest concentration applied (10 ng/mL). In
contrast, safranin O staining was already fully blocked by 1.0 ng/mL Il-1,
indicating the greater potency of Il-1 in inhibiting chondrogenesis.
Addition of osteoarthritic conditioned medium, containing an unknown
mixture of anabolic and catabolic factors, strongly inhibited chondroge-
nesis of differentiating mesenchymal stem cells. Conditioned medium
of synovia of ﬁve different patients inhibited proteoglycan deposition.
In addition, chondrogenic mRNA markers were inhibited strongly in all
patients but one, in which they were slightly stimulated. These results
show that chondrogenesis of differentiating mesenchymal stem cells is
inhibited by factors produced by OA synovium.
Conclusions: Our study shows for the ﬁrst time that chondrogenesis of
human mesenchymal stem cells is blocked by single catabolic factors as
well as factors produced by osteoarthritic synovium.
Our ﬁndings have major implications for therapies that are currently being
applied or developed. Therapies such as tissue engineering or marrow
stimulation techniques depend on tissue repair and chondrogenesis by
mesenchymal stem cells. In addition, the intrinsic repair response will be
blocked by catabolic factors present in disease joints. Successful cartilage
regeneration can be expected to fail if the catabolic environment of a
damaged joint is not altered. Our study shows that transplantation of
mesenchymal stem cells is insufﬁcient and needs to be combined with
inhibition of catabolism.
485 ALTERED CHEMOTACTIC RESPONSE OF BONE MARROW
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Purpose: Osteoarthritis (OA) is a condition that involves extensive car-
tilage and bone damage. Adult Mesenchymal Stem Cells (MSCs) are
multipotent cells whose primary reservoir is bone marrow. Following
situations of extensive tissue damage, MSC are mobilized and migrate to
the site of injury along a chemotactic gradient, contributing signiﬁcantly
to local tissue repair. Until now, various molecules that modulate chemo-
tactic migration of MSCs have been reported. Platelet-derived growth
factor (PDGF), a polypeptide formed by two amino acid chains of two
related genes, is a powerful chemotactic factor for mesenchymal cells,
including osteoblasts from human and rat tissue. The products of the
PDGF A and PDGF B genes can form homodimers or heterodimers,
so PDGF could act in three isoforms: PDGF-AA, PDGF-BB, or PDGF-
AB. PDGF-BB may be more speciﬁc for MSCs and their recruitment
from long distances, being chemoattractive for the progenitor cells even
at the lowest concentrations. The aim of this study was to assess the
chemotactic effects of PDGF-BB on primary human MSCs from patients
with OA and to compare the results with those of primary human MSCs
from healthy controls.
